TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
王金洲WANG, CHIN-CHOU
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
ccwang52@cgmh.org.tw
發表文獻
33筆
1
Chen PY, Wang CC, Hsu CN, Chen CY. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front Pharmacol. 2021;12:720687.
2
Chen YC, Tsai YH, Wang CC, Liu SF, Chen TW, Fang WF, et al. Epigenome-wide association study on asthma and chronic obstructive pulmonary disease overlap reveals aberrant DNA methylations related to clinical phenotypes. Sci Rep. 2021;11(1):5022.
3
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65.
4
Hsu CY, Tsai YH, Lin CY, Chang YC, Chen HC, Chang YP, et al. Application of a 72 h National Early Warning Score and Incorporation with Sequential Organ Failure Assessment for Predicting Sepsis Outcomes and Risk Stratification in an Intensive Care Unit: A Derivation and Validation Cohort Study. J Pers Med. 2021;11(9).
5
Huang AC, Huang CH, Ju JS, Chiu TH, Tung PH, Wang CC, et al. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211035710.
6
Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, et al. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Ther Adv Med Oncol. 2021;13:17588359211018022.
7
Lin CH, Cheng SL, Wang HC, Hsu WH, Lee KY, Perng DW, et al. Novel App-Based Portable Spirometer for the Early Detection of COPD. Diagnostics (Basel). 2021;11(5).
8
Lin CY, Wang YH, Chen YM, Hung KY, Chang YC, Fang YT, et al. Dynamic monitoring of kidney injury status over 3 days in the intensive care unit as a sepsis phenotype associated with hospital mortality and hyperinflammation. Biomed J. 2021.
9
Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, et al. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2021;2(9):100206.
10
Su PL, Tsai JS, Yang SC, Wu YL, Tseng YL, Chang CC, et al. Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer. 2021;158:137-45.
